Overview

Clobazam Use in Epilepsia Partialis Continua - Pilot Study

Status:
Terminated
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether clobazam, brand name Onf®, is more effective as an adjunctive or monotherapy in terminating Epilepsia Partialis Continua (EPC) than either lorazepam and/or clonazepam.
Phase:
Phase 3
Details
Lead Sponsor:
The Cooper Health System
Collaborator:
Lundbeck LLC
Treatments:
Clobazam
Clonazepam
Lorazepam